These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 20095990)

  • 1. Founder effect of a pathogenic MSH2 mutation identified in Spanish families with Lynch syndrome.
    Menéndez M; Castellví-Bel S; Pineda M; de Cid R; Muñoz J; González S; Teulé A; Balaguer F; Ramón y Cajal T; Reñé JM; Blanco I; Castells A; Capellà G
    Clin Genet; 2010 Aug; 78(2):186-90. PubMed ID: 20095990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of new founder Alu-mediated rearrangements in MSH2 gene associated with a Lynch syndrome phenotype.
    Pérez-Cabornero L; Borrás Flores E; Infante Sanz M; Velasco Sampedro E; Acedo Becares A; Lastra Aras E; Cuevas González J; Pineda Riu M; Ramón y Cajal Asensio T; Capellá Munar G; Miner Pino C; Durán Domínguez M
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1546-55. PubMed ID: 21778331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A common MSH2 mutation in English and North American HNPCC families: origin, phenotypic expression, and sex specific differences in colorectal cancer.
    Froggatt NJ; Green J; Brassett C; Evans DG; Bishop DT; Kolodner R; Maher ER
    J Med Genet; 1999 Feb; 36(2):97-102. PubMed ID: 10051005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New founding mutation in MSH2 associated with hereditary nonpolyposis colorectal cancer syndrome on the Island of Tenerife.
    Medina-Arana V; Barrios Y; Fernández-Peralta A; Herrera M; Chinea N; Lorenzo N; Jiménez A; Martín-López JV; González-Hermoso F; Salido E; González-Aguilera JJ
    Cancer Lett; 2006 Dec; 244(2):268-73. PubMed ID: 16500024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High frequency of exon deletions and putative founder effects in French Canadian Lynch syndrome families.
    Chong G; Jarry J; Marcus V; Thiffault I; Winocour S; Monczak Y; Drouin R; Latreille J; Australie K; Bapat B; Gordon PH; Giguère Y; Gologan A; Galiatsatos P; Jass JR; Wong N; Zaor S; Palma L; Kasprzak L; Tischkowitz M; Foulkes WD
    Hum Mutat; 2009 Aug; 30(8):E797-812. PubMed ID: 19459153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Origins and prevalence of the American Founder Mutation of MSH2.
    Clendenning M; Baze ME; Sun S; Walsh K; Liyanarachchi S; Fix D; Schunemann V; Comeras I; Deacon M; Lynch JF; Gong G; Thomas BC; Thibodeau SN; Lynch HT; Hampel H; de la Chapelle A
    Cancer Res; 2008 Apr; 68(7):2145-53. PubMed ID: 18381419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline novel MSH2 deletions and a founder MSH2 deletion associated with anticipation effects in HNPCC.
    Stella A; Surdo NC; Lastella P; Barana D; Oliani C; Tibiletti MG; Viel A; Natale C; Piepoli A; Marra G; Guanti G
    Clin Genet; 2007 Feb; 71(2):130-9. PubMed ID: 17250661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The frequency of Muir-Torre syndrome among Lynch syndrome families.
    South CD; Hampel H; Comeras I; Westman JA; Frankel WL; de la Chapelle A
    J Natl Cancer Inst; 2008 Feb; 100(4):277-81. PubMed ID: 18270343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presymptomatic diagnosis using a deletion of a single codon in families with hereditary non-polyposis colorectal cancer.
    Ripa RS; Katballe N; Wikman FP; Jäger AC; Bernstein I; Orntoft T; Schwartz M; Nielsen FC; Bisgaard ML
    Mutat Res; 2005 Feb; 570(1):89-96. PubMed ID: 15680406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of rearrangements in Lynch syndrome cases associated with MSH2: characterization of a new deletion involving both EPCAM and the 5' part of MSH2.
    Pérez-Cabornero L; Infante Sanz M; Velasco Sampedro E; Lastra Aras E; Acedo Becares A; Miner Pino C; Durán Domínguez M
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1556-62. PubMed ID: 21791569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel complex mutation in MSH2 contributes to both Muir-Torre and Lynch Syndrome.
    Perera S; Ramyar L; Mitri A; Pollett A; Gallinger S; Speevak MD; Aronson M; Bapat B
    J Hum Genet; 2010 Jan; 55(1):37-41. PubMed ID: 19911012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of Lynch syndrome in consecutive patients with colorectal cancer.
    Green RC; Parfrey PS; Woods MO; Younghusband HB
    J Natl Cancer Inst; 2009 Mar; 101(5):331-40. PubMed ID: 19244167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two Swedish founder MSH6 mutations, one nonsense and one missense, conferring high cumulative risk of Lynch syndrome.
    Cederquist K; Emanuelsson M; Wiklund F; Golovleva I; Palmqvist R; Grönberg H
    Clin Genet; 2005 Dec; 68(6):533-41. PubMed ID: 16283884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The nonsense mutation MSH2 c.2152C>T shows a founder effect in Portuguese Lynch syndrome families.
    Pinheiro M; Francisco I; Pinto C; Peixoto A; Veiga I; Filipe B; Santos C; Maia S; Silva J; Pinto P; Santos R; Claro I; Lage P; Lopes P; Ferreira S; Rosa I; Fonseca R; Rodrigues P; Henrique R; Chaves P; Pereira AD; Brandão C; Albuquerque C; Teixeira MR
    Genes Chromosomes Cancer; 2019 Sep; 58(9):657-664. PubMed ID: 30968502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MSH2 c.1022T>C, p.Leu341Pro is a founder pathogenic variation and a major cause of Lynch syndrome in the North of France.
    Vermaut C; Leclerc J; Vasseur F; Wacrenier A; Lovecchio T; Boidin D; Rebergue MH; Cattan S; Manouvrier S; Lejeune S; Buisine MP
    Genes Chromosomes Cancer; 2020 Feb; 59(2):111-118. PubMed ID: 31433521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haplotype analysis suggest that the MLH1 c.2059C > T mutation is a Swedish founder mutation.
    von Salomé J; Liu T; Keihäs M; Morak M; Holinski-Feder E; Berry IR; Moilanen JS; Baert-Desurmont S; Lindblom A; Lagerstedt-Robinson K
    Fam Cancer; 2018 Oct; 17(4):531-537. PubMed ID: 29288294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenicity of A600V variant in exon 12 of the MSH2 gene detected in a Japanese kindred with Lynch syndrome.
    Miyakura Y; Sugano K; Nomizu T; Lefor A; Yasuda Y
    Jpn J Clin Oncol; 2012 Jan; 42(1):78-82. PubMed ID: 22086974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a founder EPCAM deletion in Spanish Lynch syndrome families.
    Mur P; Pineda M; Romero A; Del Valle J; Borràs E; Canal A; Navarro M; Brunet J; Rueda D; Ramón Y Cajal T; Lázaro C; Caldés T; Blanco I; Soto JL; Capellá G
    Clin Genet; 2014 Mar; 85(3):260-6. PubMed ID: 23530899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cryptic paracentric inversion of MSH2 exons 2-6 causes Lynch syndrome.
    Liu Q; Hesson LB; Nunez AC; Packham D; Williams R; Ward RL; Sloane MA
    Carcinogenesis; 2016 Jan; 37(1):10-17. PubMed ID: 26498247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The phenotypic expression of three MSH2 mutations in large Newfoundland families with Lynch syndrome.
    Stuckless S; Parfrey PS; Woods MO; Cox J; Fitzgerald GW; Green JS; Green RC
    Fam Cancer; 2007; 6(1):1-12. PubMed ID: 17039271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.